Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jan 21;588(2):308-17.
doi: 10.1016/j.febslet.2013.11.027. Epub 2013 Nov 26.

Mass spectrometry for the biophysical characterization of therapeutic monoclonal antibodies

Affiliations
Review

Mass spectrometry for the biophysical characterization of therapeutic monoclonal antibodies

Hao Zhang et al. FEBS Lett. .

Abstract

Monoclonal antibodies (mAbs) are powerful therapeutics, and their characterization has drawn considerable attention and urgency. Unlike small-molecule drugs (150-600 Da) that have rigid structures, mAbs (∼150 kDa) are engineered proteins that undergo complicated folding and can exist in a number of low-energy structures, posing a challenge for traditional methods in structural biology. Mass spectrometry (MS)-based biophysical characterization approaches can provide structural information, bringing high sensitivity, fast turnaround, and small sample consumption. This review outlines various MS-based strategies for protein biophysical characterization and then reviews how these strategies provide structural information of mAbs at the protein level (intact or top-down approaches), peptide, and residue level (bottom-up approaches), affording information on higher order structure, aggregation, and the nature of antibody complexes.

Keywords: FPOP; Hydrogen/deuterium exchange; Ion mobility; Mass spectrometry; Monoclonal antibody; Native ESI; Protein footprinting; Top-down and bottom-up.

PubMed Disclaimer

Figures

Figure 1
Figure 1
IgG structure (IgG1). The global structure of IgG1 has two identical heavy chains and light chains. Four chains are attached covalently with inter-chain disulfide bonds and also by non-covalent interactions. The two constant regions from heavy chains (CH2 and CH3, Fc regions) respond to the binding to Fc gamma and FcRn receptors. The variable region from both light and heavy chains contains antigen-binding regions (CDRs). Variable regions with the close constant region together are called the Fab region. The Fab and Fc region are linked by the hinge region in the heavy chain. In the IgG1, there is a glycosylation site on the second constant region (CH2).
Figure 2
Figure 2
Overview of top-down and bottom-up MS based protein biophysical studies. The left circle is the summary of top-down approaches. The right circle is the summary of bottom-up approaches.
Figure 3
Figure 3
Native ESI, IM and ECD mass spectra of WT IgG2, (a) ion mobility separation, (b) ECD top-down with in-source activation, and (c) highlighted region in yellow of light chain in CDR showing ECD cleavage sites. (Copied with permission from JASMS)
Figure 4
Figure 4
The MS based biophysical “tool box” in characterizations of IgG2 with different S-S bond networks. This is an example of combining multiple approaches, not limited to MS, to provide complementary structural information of mAbs. The experimental time scale and structural resolution are labeled.

Similar articles

Cited by

References

    1. Buss NA, Henderson SJ, McFarlane M, Shenton JM, de Haan L. Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol. 2012;12:615–22. - PubMed
    1. Larrick JW. Conference scene: progress with promising human antibodies. Immunotherapy. 2012;4:257–61. - PubMed
    1. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010;9:767–74. - PubMed
    1. Metzger H, Kinet JP. How antibodies work: focus on Fc receptors. FASEB J. 1988;2:3–11. - PubMed
    1. Raghavan M, Bjorkman PJ. Fc receptors and their interactions with immunoglobulins. Annu Rev Cell Dev Biol. 1996;12:181–220. - PubMed

Publication types

Substances